Structural Formula (Image 01)
Fosaprepitant Injection, Powder, Lyophilized, For Solution
Product Images NDC 67457-889
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Fosaprepitant (NDC 67457-889). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Image 02)
This is a pharmacokinetic graph showing the mean plasma concentration of Aprepitant, a drug used for chemotherapy-induced nausea and vomiting, after oral administration of 125mg Aprepitant and intravenous administration of 115mg Fosaprepitant. The graph shows the concentration levels over a period of up to 72 hours after dosing.*
Figure 2 (Image 03)
This is a figure demonstrating the percentage of patients who received highly emetogenic chemotherapy and remained free of vomiting over time in cycle 1. There are two studies being compared; Study 1 and Study 2. The figure shows that patients who received the Aprepitant Regimen had a higher percentage of remaining emesis free compared to those who received the Standard treatment. The percentage of patients is plotted against time in hours, with intervals of 24 hours up to 120 hours.*
Figure 3 (Image 04)
This is a graph showing the proportion of patients who received highly emetogenic chemotherapy and experienced no emesis and no significant nausea by treatment group and cycle during Study 1 and Study 2. The graph includes data for patients receiving the Aprepitant regimen and those who received standard therapy. The x-axis represents chemotherapy cycle and the y-axis represents the proportion of patients.*
115 mg-carton (Image 05)
Fosaprepitant is a sterilized lyophilized powder for intravenous use that needs to be refrigerated between 2-8°C (36°F to 46°F). Each vial contains 188 mg of fosaprepitant dimeglumine equivalent to 115 mg of fosaprepitant, which after being reconstituted with 5 mL0.9% Sodium Chloride, becomes an infusion. The reconstituted solution must not be kept for more than 24 hours at or below 25°C (77°F). The usual dosage is not provided. Inactive ingredients include Edetate disodium, polysorbate 80, actose anhydrous, and sodium hydoxde and/or hydrochloric acid for pH adjustment. It also provides preparation steps, with each vial being single-dose only, and unused portions of the solution must be discarded. The description also includes warnings, including that the drug should not be used with solutions containing divalent cations such as Calcium and Magnesium, including lactated Ringer's Solution.*
Carton-150 mg (Image 06)
Fosaprepitant for Injection is a medication that comes in a single-use vial containing 245.3 mg of fosaprepitant dimeglumine equivalent to 150 mg of fosaprepitant. The solution must be reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, and the final drug solution is stable for 24 hours at or below 25°C. The medication cannot be used with solutions containing divalent cations such as Ca or Mg, including lactated Ringer's solution and Hartmann's Solution. It is only for intravenous use and must be discarded after one use. The ingredients of the medication also include edetate disodium, polysorbate 80, lactose anhydrous, and sodium hydroxide and/or hydrochloric acid (for pH adjustment), and it must be refrigerated at 2°C to 8°C.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
